Peddock Capital Advisors LLC Buys 176 Shares of Danaher Co. (NYSE:DHR)

Peddock Capital Advisors LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 3.2% in the 4th quarter, Holdings Channel reports. The institutional investor owned 5,699 shares of the conglomerate’s stock after purchasing an additional 176 shares during the quarter. Peddock Capital Advisors LLC’s holdings in Danaher were worth $1,318,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Danaher by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,718,735 shares of the conglomerate’s stock worth $860,292,000 after purchasing an additional 95,440 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Danaher by 165.9% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,868 shares of the conglomerate’s stock valued at $2,052,000 after acquiring an additional 5,533 shares in the last quarter. Apollon Wealth Management LLC boosted its holdings in shares of Danaher by 50.3% in the fourth quarter. Apollon Wealth Management LLC now owns 20,312 shares of the conglomerate’s stock valued at $4,699,000 after purchasing an additional 6,799 shares during the period. Fielder Capital Group LLC bought a new position in Danaher in the fourth quarter worth approximately $203,000. Finally, Maryland State Retirement & Pension System increased its holdings in Danaher by 1.1% during the 4th quarter. Maryland State Retirement & Pension System now owns 51,241 shares of the conglomerate’s stock worth $11,854,000 after purchasing an additional 545 shares during the period. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other Danaher news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,984 shares of company stock valued at $25,997,094. Corporate insiders own 10.90% of the company’s stock.

Danaher Price Performance

DHR traded up $0.47 during trading on Wednesday, hitting $249.23. The company’s stock had a trading volume of 761,053 shares, compared to its average volume of 2,721,560. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $184.60 billion, a price-to-earnings ratio of 42.18, a P/E/G ratio of 3.82 and a beta of 0.83. The business’s fifty day simple moving average is $248.27 and its 200 day simple moving average is $233.19. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s revenue was down 2.6% compared to the same quarter last year. During the same period last year, the firm posted $2.36 earnings per share. On average, equities research analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. Danaher’s payout ratio is presently 18.31%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Barclays increased their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 24th. KeyCorp increased their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Raymond James upped their target price on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Robert W. Baird lifted their price target on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Finally, Royal Bank of Canada upped their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $267.31.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.